The CML Society of Canada has been invited to provide input to the Pan Canadian Oncology Drug Review regarding the process that will eventually determine whether iClusig will be reimbursed through the various provincial bodies.
The Pan Canadian Oncology Drug Review analyzes information from Oncologists, Health Care Economists, Patients and the manufacturers. The outcome is to determine the clinical and cost effectiveness of the drug. Patient groups have worked very hard to ensure that the cancer patients voice is heard. It is important for us to get as much input as possible.
The manufacturer has indicated that they will seek funding for ponatinib (Iclusig) for treatment of adult patients with chronic phase, accelerated phase, or blast phase chronic myeloid leukemia (CML) or Philadelphia chromosome positive acute lymphoblastic leukemia (Ph+ ALL) with or without the T315I mutation, resistant or intolerant to previous tyrosine kinase inhibitor therapy, and for whom other tyrosine kinase inhibitors are not appropriate.
If you are taking iClusig (Ponatinib), and are a Canadian resident, please contact us as soon as possible directly to email@example.com who will schedule your interview with Ms. Sandra Shaw (Masters Candidate, McGill University- Bioethics) our bioethicist.
The deadline for our submission is for early March.
Make sure your voice is heard!